San Diego-based Viking Therapeutics marked alone as a significant competitor in the weight loss drug market in February just after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection and in March the company unveiled